Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Alemtuzumab in T-cell large granular lymphocytic leukaemia: a phase 2 study Dumitriu Bogdan MD1Ito Sawa MD1Feng Xingmin PhD1Stephens Nicole MS1Yunce Muharrem MD1Kajigaya Sachiko PhD1Melenhorst32 passages
• Alliance Risk Profile): a development and validation study Cook Gordon ProfPhDg.cook@leeds.ac.ukab*Royle Kara-Louise MScbPawlyn Charlotte PhDcHockaday Anna BScbShah Vallari MBBScKaiser47 passages
• CMV Viral Load and Mortality after Hematopoietic Cell Transplantation: A Cohort Study in the Era of Preemptive Therapy Green26 passages
• Center, 1100 Fairview6 passages
• Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study Ndila44 passages
• Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study Snijder Berend ProfPhDab*Vladimer38 passages
• Institute of City of Hope, and City of Hope Comprehensive Cancer Center, Duarte, CA, USAUniversity of Minnesota Medical Center, Medicine/Blood and Marrow Transplantation, Minneapolis, MN (Prof45 passages
• Lancet Haematol355 passages
• Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan Nieto29 passages
• Programme, Centre for Geographic Medicine Research-Coast, PO Box 230, Kilifi 80108, KenyaCorrespondence to: Prof31 passages
• Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors Sasaki Koji MD12Strom42 passages
• Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial Cox49 passages
• Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A35 passages
• UK, Celgene, Amgen, Merck,49 passages
• UK, Sporting Chance Cancer Foundation, National Health and Medical Research Council Australia, KindreneKankervrij Netherlands, European Union Seventh Framework Programme, India Alliance40 passages
• Unit, Guy's and St Thomas'45 passages
• Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma Holstein40 passages